A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

Vadhan-Raj, S; Fayad, L E; Fanale, M A; Pro, B; Rodriguez, A; Hagemeister, F B; Bueso-Ramos, C E; Zhou, X; McLaughlin, P W; Fowler, N; Shah, J; Orlowski, R Z; Samaniego, F; Wang, M; Cortes, J E; Younes, A; Kwak, L W; Sarlis, N J; Romaguera, J E

Vadhan-Raj, S; Fayad, L E; Fanale, M A; Pro, B; Rodriguez, A; Hagemeister, F B; Bueso-Ramos, C E; Zhou, X; McLaughlin, P W; Fowler, N; Shah, J; Orlowski, R Z; Samaniego, F; Wang, M; Cortes, J E; Younes, A; Kwak, L W; Sarlis, N J; Romaguera, J E.

Affiliation

Vadhan-Raj S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, MD, USA. svadhanr@mdanderson.org

Ann Oncol ; 23(6): 1640-5, 2012 Jun.

Article in En | MEDLINE | ID: mdl-22015451

Subject(s)

Gout Suppressants/administration & dosage; Tumor Lysis Syndrome/prevention & control; Urate Oxidase/administration & dosage; Adult; Aged; Aged, 80 and over; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Female; Gout Suppressants/therapeutic use; Humans; Lymphoma, Large B-Cell, Diffuse/drug therapy; Male; Middle Aged; Risk Factors; Treatment Outcome; Tumor Lysis Syndrome/etiology; Urate Oxidase/therapeutic use; Uric Acid/blood

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urate Oxidase / Tumor Lysis Syndrome / Gout Suppressants Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2012 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google